The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Weight loss medications can reduce the efficacy of oral contraceptives. What to know before taking drugs like Ozempic, ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

See how GLP-1 drugs reduce heart and kidney complications in MGUS and diabetes—explore the clinical evidence. Keep reading!

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.